Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Celanese
Deal Size : Undisclosed
Deal Type : Collaboration
Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments
Details : VitalDose® EVA drug delivery platform will be used in the development of Alessa Therapeutics’ proprietary localized drug delivery technology. The collaboration will focus on developing a localized and sustained-release drug delivery system for oncolog...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Celanese
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2020
Lead Product(s) : Bicalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable